Skip to main content
. Author manuscript; available in PMC: 2017 Jun 20.
Published in final edited form as: Cancer Lett. 2014 Oct 29;357(1):1–7. doi: 10.1016/j.canlet.2014.10.028

Table 2.

Comparison of toxicities. Three landmark trials using bevacizumab (E2100, AVADO, RIBBON-1) are compared here for generally accepted chemotherapeutic toxicities such as bone marrow suppression (neutropenia), as well as bevacizumab-specific toxicities such as proteinuria, hypertension.

E2100
AVADO
RIBBON-1
Adverse events
[Grades 3 & 4]		 Paclitaxel
only		 Paclitaxel +
10 beva		 Docetaxel +
placebo		 Docetaxel +
7.5 beva		 Docetaxel +
15 beva		 Capecitabine +
placebo		 Capecitabine +
15 beva		 Tax +
placebo		 Tax +
15 beva		 Anthrac +
placebo		 Anthrac +
15 beva
Hypertension (%) 0 14.8   1.3   0.8   4.5 1 10.1 2 8.9 0 10.5
Bleeding (%) 0   0.5   0.9   1.2   0.8 0.5   0.2 0 5.4 0   1.0
Proteinuria (%) 0   3.5   0   0.8   2 0   2.2 0 3.9 0   2.9
Neutropenia (%) 0.3   0 17.3 19.8 19.8 1.0   1.2 4.9 9.4 4.0   4.3
Febrile neutropenia (%) 0   0.8 11.3 15.1 16.2 0   0 2.0 8.4 5.0   3.8
Peripheral edema (%) Not Provided Not Provided   2.6   1.2   0.4 Not Provided Not Provided Not Provided Not Provided Not Provided Not Provided